NYSE: TMO |
| Healthcare / Medical Diagnostics & Research / USA |
549.24 | -1.50 | -0.27% | Vol 1.53M | 1Y Perf 18.36% |
May 20th, 2022 15:34 DELAYED |
BID | 549.09 | ASK | 549.42 | ||
Open | 558.92 | Previous Close | 550.74 | ||
Pre-Market | 554.60 | After-Market | - | ||
3.86 0.70% | - - |
Target Price | 663.79 | Analyst Rating | Strong Buy 1.50 | |
Potential % | 21.55 | Finscreener Ranking | ★★★ 49.66 | |
Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | ★★+ 49.16 | |
Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | ★★★★ 60.26 | |
Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | ★+ 36.70 | |
Price Range Ratio 52W % | 47.31 | Earnings Rating | Strong Buy | |
Market Cap | 215.01B | Earnings Date | 28th Apr 2022 | |
Alpha | 0.01 | Standard Deviation | 0.06 | |
Beta | 0.83 |
Today's Price Range 544.44565.92 | 52W Range 438.72672.34 | 5 Year PE Ratio Range 27.2058.10 |
Summary:
Neutral
Technical Indicators: | Neutral |
Moving Averages: | Sell |
Performance | |||
---|---|---|---|
1 Week | 1.72% | ||
1 Month | -6.84% | ||
3 Months | 2.53% | ||
6 Months | -13.41% | ||
1 Year | 18.36% | ||
3 Years | 109.48% | ||
5 Years | 221.08% | ||
10 Years | 1 014.30% |
Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
ROE (5Y Avg) | 11.95 | |||
ROE last 12 Months | 20.53 | |||
ROA (5Y Avg) | 4.37 | |||
ROA last 12 Months | 9.81 | |||
ROC (5Y Avg) | 7.64 | |||
ROC last 12 Months | 12.58 | |||
Return on invested Capital Q | 3.09 | |||
Return on invested Capital Y | 2.63 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 5.40 |
Valuation | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
28.20 | ||||
5.17 | ||||
5.13 | ||||
22.50 | ||||
-18.40 | ||||
24.05 | ||||
-10.52 | ||||
104.62 | ||||
242.45B | ||||
Forward PE | 22.09 | |||
PEG | 2.17 |
Financial Strength | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
1.00 | ||||
1.60 | ||||
0.43 | ||||
0.81 | ||||
16.70 | ||||
Leverage Ratio | 2.10 |
Profitability | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
48.40 | ||||
22.30 | ||||
29.20 | ||||
17.20 | ||||
18.52 |
Revenue | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
41.12B | ||||
105.05 | ||||
17.14 | ||||
15.38 |
Dividends | Value | Industry | S&P 500 | US Markets |
---|---|---|---|---|
0.22 | ||||
1.20 | ||||
13.62 | ||||
12.29 | ||||
Payout ratio | 4.00 |
Earnings History | Estimate | Reported | Surprise % |
---|---|---|---|
Q01 2022 | 6.17 | 7.25 | 17.50 |
Q04 2021 | 5.22 | 6.54 | 25.29 |
Q03 2021 | 4.67 | 5.76 | 23.34 |
Q02 2021 | 5.51 | 5.60 | 1.63 |
Q01 2021 | 6.69 | 7.21 | 7.77 |
Q04 2020 | 6.86 | 7.09 | 3.35 |
Q03 2020 | 4.37 | 5.63 | 28.83 |
Q02 2020 | 2.67 | 3.89 | 45.69 |
Earnings Per End | Estimate | Revision % | Trend |
---|---|---|---|
6/2022 QR | 4.93 | -9.71 | Negative |
9/2022 QR | 4.93 | -2.57 | Negative |
12/2022 FY | 22.68 | 0.71 | Positive |
12/2023 FY | 24.50 | 1.83 | Positive |
Next Report Date | - |
Estimated EPS Next Report | 6.17 |
Estimates Count | 8 |
EPS Growth Next 5 Years % | 13.00 |
Volume Overview | |
---|---|
Volume | 1.53M |
Shares Outstanding | 391.46K |
Shares Float | 390.91M |
Trades Count | 45.62K |
Dollar Volume | 848.88M |
Avg. Volume | 1.49M |
Avg. Weekly Volume | 1.39M |
Avg. Monthly Volume | 1.60M |
Avg. Quarterly Volume | 1.48M |
Thermo Fisher Scientific Inc (NYSE: TMO) stock closed at 550.74 per share at the end of the most recent trading day (a 1.58% change compared to the prior day closing price) with a volume of 1.98M shares and market capitalization of 215.01B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 75000 people. Thermo Fisher Scientific Inc CEO is Marc N. Casper.
The one-year performance of Thermo Fisher Scientific Inc stock is 18.36%, while year-to-date (YTD) performance is -17.46%. TMO stock has a five-year performance of 221.08%. Its 52-week range is between 438.72 and 672.34, which gives TMO stock a 52-week price range ratio of 47.31%
Thermo Fisher Scientific Inc currently has a PE ratio of 28.20, a price-to-book (PB) ratio of 5.17, a price-to-sale (PS) ratio of 5.13, a price to cashflow ratio of 22.50, a PEG ratio of 2.32, a ROA of 9.81%, a ROC of 12.58% and a ROE of 20.53%. The company’s profit margin is 18.52%, its EBITDA margin is 29.20%, and its revenue ttm is $41.12 Billion , which makes it $105.05 revenue per share.
Of the last four earnings reports from Thermo Fisher Scientific Inc, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $6.17 for the next earnings report. Thermo Fisher Scientific Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for Thermo Fisher Scientific Inc is Strong Buy (1.5), with a target price of $663.79, which is +21.55% compared to the current price. The earnings rating for Thermo Fisher Scientific Inc stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Thermo Fisher Scientific Inc has a dividend yield of 0.22% with a dividend per share of $1.20 and a payout ratio of 4.00%.
Thermo Fisher Scientific Inc has a Neutral technical analysis rating based on Technical Indicators (ADX : 7.92, ATR14 : 18.94, CCI20 : 45.36, Chaikin Money Flow : -0.10, MACD : -6.27, Money Flow Index : 46.11, ROC : 0.81, RSI : 50.45, STOCH (14,3) : 72.02, STOCH RSI : 0.91, UO : 52.37, Williams %R : -27.98), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Thermo Fisher Scientific Inc in the last 12-months were: Debora L. Spar (Sold 200 shares of value $108 872 ), Jim P. Manzi (Sold 2 072 shares of value $1 152 824 ), Joseph Holmes (Option Excercise at a value of $150 440), Joseph Holmes (Sold 759 shares of value $411 948 ), Marc N. Casper (Option Excercise at a value of $3 893 100), Marc N. Casper (Sold 67 600 shares of value $36 638 688 ), Mark P. Stevenson (Option Excercise at a value of $35 021 908), Mark P. Stevenson (Sold 188 475 shares of value $116 870 117 ), Michel Lagarde (Sold 6 100 shares of value $3 301 890 ), Stephen Williamson (Option Excercise at a value of $2 926 313), Stephen Williamson (Sold 22 550 shares of value $14 389 043 )
Analyst Ratings | Current | 1 M ago | 3 M ago |
---|---|---|---|
Strong Buy | |||
Moderate Buy | |||
Hold | |||
Moderate Sell | |||
Strong Sell | |||
Summary Rating | Strong Buy | Strong Buy | Strong Buy |
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments (revenue figures include some cross-segment revenue): analytical technologies (16% of sales); specialty diagnostic products (17%); life science solutions (38%); and lab products and services (38%).
CEO: Marc N. Casper
Telephone: +1 781 622-1000
Address: 168 Third Avenue, Waltham 02451, MA, US
Number of employees: 75 000
Fri, 20 May 2022 03:56 GMT Thermo Fisher (TMO) Received its Third Buy in a Row
- TipRanks. All rights reserved.Fri, 20 May 2022 03:55 GMT Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Thermo Fisher (TMO) and Atreca (BCEL)
- TipRanks. All rights reserved.Tue, 10 May 2022 09:02 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Thermo Fisher (TMO), Galecto (GLTO) and Eledon Pharmaceuticals (ELDN)
- TipRanks. All rights reserved.Wed, 02 Mar 2022 10:18 GMT Inside Thermo Fishers Newly Added Risk Factors
- TipRanks. All rights reserved.Sun, 27 Feb 2022 10:39 GMT Thermo Fisher (TMO) Gets a Buy Rating from Credit Suisse
- TipRanks. All rights reserved.Thu, 24 Feb 2022 17:53 GMT Thermo Fisher Scientific: Strong Growth, Relatively Overvalued
- TipRanks. All rights reserved.Wed, 09 Feb 2022 16:13 GMT Thermo Fisher Scientific: Strong Q4, Forward EPS Estimates
- TipRanks. All rights reserved.Sun, 06 Feb 2022 13:42 GMT Thermo Fisher (TMO) Gets a Buy Rating from Robert W. Baird
- TipRanks. All rights reserved.Sun, 06 Feb 2022 13:42 GMT Thermo Fisher (TMO) Gets a Buy Rating from Leerink Partners
- TipRanks. All rights reserved.Thu, 27 Jan 2022 17:33 GMT Thermo Fisher Scientific: Recent Correction Proves Compelling
- TipRanks. All rights reserved.Thu, 06 Jan 2022 14:08 GMT Thermo Fisher (TMO) Receives a Buy from Leerink Partners
- TipRanks. All rights reserved.Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
All rights reserved. Financial Market Data powered by Quotemedia.com. All rights reserved. View the Terms of Use. CBOE EDGX Top real-time data for Premium users, NYSE/NYSE MKT (AMEX) data delayed 20 minutes. NASDAQ and other data delayed 15 minutes unless otherwise indicated. Technology and data provided by TeleTrader. Conditions of Use. The regulations of the respective stock are to be observed. Copyright © 2022. All market data is provided by Quotemedia.com. Futures: at least a 10 minute delay. Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer. The Cryptocurrency Market real-time data provided by Cryptocompare.com
eToro USA LLC does not offer CFDs and makes no representation and assumes no liability as to the accuracy or completeness of the content of this publication, which has been prepared by our partner utilizing publicly available non-entity specific information about eToro. Your capital is at risk.
Don´t have an account? Register
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.